US Edition
Weight-loss jabs can help you live longer
- Novo Nordisk presented new data from the Select trial showing Wegovy, containing semaglutide, rapidly reduces heart attack, stroke, and death risk in high-risk overweight patients.
- The randomized, double-blind Select trial enrolled 17,604 participants with established cardiovascular disease and obesity to assess semaglutide 2.4mg versus placebo for preventing cardiovascular events.
- Analysis showed a 37% reduction in major cardiovascular events within three months and a 50% decrease in cardiovascular death within six months, with effects appearing before significant weight loss.
- Lead author Dr. Jorge Plutzky stated semaglutide produced early treatment separation prior to full dosage or notable weight loss, and Professor Donna Ryan called the data definite proof of cardiovascular risk reduction.
- These findings support early initiation of Wegovy in high-risk patients to reduce cardiovascular events, but further research is needed to clarify the mechanisms and confirm long-term benefits.
Insights by Ground AI
Does this summary seem wrong?
13 Articles
13 Articles
All
Left
3
Center
4
Right
1
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Novo Nordisk (NYSE:NVO), Septerna (NASDAQ:SEPN)
Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.
·New York, United States
Read Full Article
Coverage Details
Total News Sources13
Leaning Left3Leaning Right1Center4Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 38%
C 50%
13%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
